Stevens Capital Management LP cut its holdings in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 43.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 34,075 shares of the biopharmaceutical company’s stock after selling 26,392 shares during the period. Stevens Capital Management LP owned approximately 0.07% of Sucampo Pharmaceuticals worth $402,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. HPM Partners LLC acquired a new stake in Sucampo Pharmaceuticals during the second quarter valued at approximately $1,307,000. Louisiana State Employees Retirement System lifted its position in shares of Sucampo Pharmaceuticals by 1.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 100 shares in the last quarter. Nine Chapters Capital Management LLC purchased a new stake in shares of Sucampo Pharmaceuticals in the 3rd quarter valued at approximately $127,000. First Citizens Bank & Trust Co. purchased a new stake in shares of Sucampo Pharmaceuticals in the 2nd quarter valued at approximately $116,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Sucampo Pharmaceuticals in the 2nd quarter valued at approximately $117,000. 65.31% of the stock is owned by institutional investors and hedge funds.
In other Sucampo Pharmaceuticals news, insider Jason Patrick Meyenburg purchased 4,000 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were bought at an average price of $12.13 per share, for a total transaction of $48,520.00. Following the purchase, the insider now directly owns 30,228 shares in the company, valued at approximately $366,665.64. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $12.00, for a total transaction of $12,000,000.00. The disclosure for this sale can be found here. 4.13% of the stock is owned by corporate insiders.
Several brokerages recently commented on SCMP. ValuEngine upgraded shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday. began coverage on shares of Sucampo Pharmaceuticals in a research report on Wednesday, November 15th. They issued a “buy” rating and a $14.00 price target for the company. B. Riley began coverage on shares of Sucampo Pharmaceuticals in a research report on Tuesday, November 14th. They issued a “buy” rating and a $14.00 price target for the company. Maxim Group restated a “buy” rating and issued a $23.00 price target on shares of Sucampo Pharmaceuticals in a research report on Thursday, November 2nd. Finally, Mizuho restated a “hold” rating and issued a $12.00 price target on shares of Sucampo Pharmaceuticals in a research report on Wednesday, November 1st. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $16.00.
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) traded up $0.65 during mid-day trading on Monday, reaching $13.45. 4,770,203 shares of the company’s stock were exchanged, compared to its average volume of 686,065. Sucampo Pharmaceuticals, Inc. has a 12 month low of $9.30 and a 12 month high of $17.24. The company has a current ratio of 5.11, a quick ratio of 4.46 and a debt-to-equity ratio of 7.37. The stock has a market cap of $598.12, a P/E ratio of 8.77, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.02. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The company had revenue of $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. During the same quarter in the prior year, the firm earned $0.30 EPS. The company’s revenue was up 5.9% compared to the same quarter last year. analysts expect that Sucampo Pharmaceuticals, Inc. will post 1.12 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Stevens Capital Management LP Has $402,000 Stake in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/04/sucampo-pharmaceuticals-inc-scmp-position-reduced-by-stevens-capital-management-lp.html.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.